Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Hydroxychloroquine is a drug that has been used to treat malaria and rheumatism. It is recently discovered that Hydroxychloroquine increases 'autophagy'. Autophagy is a process whereby cells eat a part themselves giving them extra energy. Cancer cells use autophagy to survive chemotherapy or hormonal therapy. Also, cancer cells use autophagy to survive in areas of a tumor where there is a low oxygen level.

The purpose of this study is to determine whether treatment with the drug Hydroxychloroquine leads to a decrease of autophagy in breast cancer tissue.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• Patients with core-biopsy proven invasive adenocarcinoma of the breast

• Any tumor with a size ≥ 1cm (NOT inflammatory breast cancer)

• WHO-performance score 0 or 1

• Written informed consent

Exclusion Criteria:

• Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol

• Hampered liver or kidney function

• Serious gastro-intestinal disease

• Neurological disease (including epilepsy)

• Hematological disease

• Psoriasis

• Porphyry

• G6PD deficiency

• Hypersensitivity for quinine

• Use of gold containing drugs, oxyphenbutazone, phenylbutazon, digoxin

• Operation for breast cancer foreseen within 14 days after inclusion in the study.